Zynyz authorised for advanced Merkel cell carcinoma
- Sponsor
- Incyte Biosciences UK Ltd
- Drug
- Zynyz · retifanlimab
- Indication
- Metastatic or recurrent locally advanced Merkel cell carcinoma in adults
MHRA authorised Incyte's Zynyz (retifanlimab) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Zynyz is a humanised anti-PD-1 monoclonal antibody previously FDA-approved for this indication in March 2023; the UK authorisation adds the second major-market approval for a treatment class that has substantially reshaped outcomes in an aggressive skin cancer historically treated with chemotherapy.
Read original at gov.uk ↗From the source
MHRA approves retifanlimab (Zynyz) for the treatment of advanced Merkel cell skin cancer
From: Medicines and Healthcare products Regulatory Agency Published: 6 July 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has today approved retifanlimab (Zynyz) for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.
Merkel cell carcinoma is a rare and aggressive form of skin cancer.
Zynyz is a humanised monoclonal antibody targeting the PD-1 receptor on immune cells. By blocking PD-1, the drug removes a brake on the immune system's ability to recognise and attack cancer cells.
As with any medicinal product, the MHRA will keep the safety and effectiveness of retifanlimab under close review.
Reproduced from MHRA News · view original · public domain or open-licensed government work
Drug Watch — recent news on Zynyz
- Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
- MHRA approves retifanlimab for rare skin cancer - The Pharma Letter
- MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer - GOV.UK
- UK's MHRA Approves Retifanlimab For Treatment Of Advanced Merkel Cell Skin Cancer - TradingView
- UK Regulator Approves Breakthrough Immunotherapy for Rare Merkel Cell Skin Cancer - streamlinefeed.co.ke